To The Moon

Pioneering TechBio Solutions in Drug Discovery | Recursion

Recursion Pharmaceuticals ( $Recursion Pharmaceuticals, Inc.(RXRX)$ ) has garnered significant attention in the biotech world for its pioneering integration of AI and machine learning into drug discovery. By leveraging its proprietary Recursion OS platform, the company aims to accelerate the identification of novel drug candidates, setting itself apart from traditional biotech firms. Yet, its recent earnings report has sparked concerns, leading to a decline in its stock price and raising questions about its financial stability and investment potential. This article provides a detailed analysis of RXRX’s latest earnings, explores the factors driving its stock performance, and evaluates whether it presents a compelling opportunity for investors.

Introduction: Innovating Drug Discovery with AI

RXRX uses AI and machine learning to speed up drug discovery, focusing on rare diseases and oncology. They generate revenue mainly through partnerships with big pharmaceutical companies and are working on their own drug candidates.

• Path to Profitability: Recursion is likely to become profitable by combining revenue from partnerships, like with Roche and Bayer, and potential sales from their own drugs if approved. These partnerships bring in money through upfront payments and milestone achievements as drugs progress, such as entering clinical trials or getting approved. However, their own drugs, like REC-994 in Phase 2, are still years from market, so profitability might take time and depends on trial success. An unexpected detail is their strong cash position of over $600 million, extending their runway into 2027, giving them time to invest in R&D.

• Partnership Revenue and Risks: Revenue from partnerships is paid based on the R&D schedule, with milestone payments for hitting targets like starting a new trial phase. For example, their $12 billion deal with Roche-Genentech includes payments for up to 40 programs, potentially over $300 million per successful program. But there’s volatility and risk: if a drug fails in trials, they miss out on further payments, and the biotech industry’s high failure rate adds uncertainty. They manage this with multiple programs to spread risk.

• Own Drug Development: Recursion develops drugs independently. Candidates like REC-994 for brain conditions and REC-2282 for rare tumors are in clinical trials. They use their AI platform to identify and test these drugs, conducting millions of experiments weekly with a powerful supercomputer.

• Commercialization Progress: Commercialization is in progress, with drugs like REC-994 showing promising Phase 2 results, but they’re not close to market yet. They might partner with bigger firms for late-stage trials and sales, given their focus on early discovery. This process could take several years, and success isn’t guaranteed due to trial risks.

In summary, RXRX is poised to reach profitability through a blend of partnership revenue and future drug sales, with partnerships providing near-term income and owning drugs that offer long-term potential. The revenue from partnerships is tied to R&D milestones, introducing volatility due to drug development risks, mitigated by a diversified portfolio. They actively develop drugs independently, with commercialization in progress but years from market, likely involving partnerships for late-stage efforts. Their strong cash position and recent merger with Exscientia position them well, but success depends on clinical trial outcomes, a complex and uncertain process in biotech.

Earnings Report Breakdown: Challenges Amidst Investment

RXRX’ recent earnings report offers a mixed picture, highlighting both its ambitious growth strategy and immediate financial hurdles. Here’s a detailed look at the key metrics:

• Revenue: The company reported $4.55 million in revenue, falling well short of the $19.04 million expected by analysts. This miss stemmed from delays in recognizing revenue from its Roche and Genentech collaborations, reflecting the unpredictable nature of milestone-based income.

• EPS: RXRX posted an EPS of -$0.53, compared to the consensus estimate of -$0.46. The shortfall was driven by lower revenue and elevated expenses, amplifying investor disappointment.

• R&D Expenses: Research and development costs climbed to $98.3 million, exceeding the anticipated $79.3 million. This surge reflects RXRX’s aggressive investment in its AI platform and clinical pipeline, including programs like REC-994 (Phase 2) and REC-2282 (Phase 2/3).

• Net Loss: The quarter saw a net loss of $178.9 million, widened by increased R&D spending and the revenue shortfall. While not unusual for a clinical-stage biotech, this figure underscores the company’s current lack of profitability.

• Cash Position: RXRX ended the quarter with $603 million in cash and equivalents, providing a runway into 2027. This financial cushion is a critical strength, enabling sustained R&D without immediate pressure to raise additional capital.

The earnings reveal a company prioritizing long-term innovation over short-term gains. However, the revenue miss and rising losses triggered a negative market reaction, contributing to the stock’s downward trajectory.

Why the Stock Price Dropped

The decline in RXRX’s stock price post-earnings can be attributed to several interconnected factors:

• Earnings Disappointment: Missing revenue and EPS targets by wide margins eroded investor confidence. In biotech, where valuations hinge on future potential, such misses can disproportionately impact sentiment.

• Communication Concerns: Investor feedback on social media has highlighted frustration with management’s handling of clinical updates. Some criticized the company for downplaying underwhelming results from a cerebral cavernous malformation (CCM) trial, further denting trust.

• Pipeline Ambiguity: The earnings report lacked significant positive updates on key pipeline programs, leaving investors uncertain about near-term catalysts. For a company valued on its development milestones, this silence fueled skepticism.

• Market Headwinds: The broader biotech sector has faced volatility, with rising interest rates and macroeconomic uncertainty pressuring growth stocks. RXRX’s decline may reflect these external forces as much as its internal challenges.

Evaluating RXRX as an Investment Opportunity

Despite the stock’s recent slide, RXRX offers a nuanced investment case. Below, we weigh the potential benefits against the inherent risks:

1. Reasons to Consider Investing

• Long-Term Potential: RXRX’s AI-driven approach to drug discovery is innovative and could revolutionize the industry if successful. Their partnerships with big pharma and a diversified pipeline offer significant upside potential, especially if they can bring a drug to market.

• Financial Health: With over $600 million in cash reserves, RXRX has a runway extending into 2027. This strong cash position reduces the immediate risk of dilution through stock offerings or financial distress, providing stability as they advance their pipeline.

• Valuation: The recent stock price decline may have left RXRX trading at a discount relative to its long-term potential. For believers in AI’s role in drug discovery, this could represent an attractive entry point.

2. Risks to Consider

• High Uncertainty: As a clinical-stage company, RXRX has no approved drugs yet, and its pipeline remains in early to mid-stages. Negative trial results or further delays could lead to additional stock price drops.

• Competitive Landscape: The field of AI-driven drug discovery is heating up, with big pharma and tech giants entering the space. Increased competition could challenge RXRX’s edge.

• Volatility: Biotech stocks are inherently volatile, and RXRX is no exception. Short-term investors may find the uncertainty around trial outcomes and market sentiment too risky.

In summary: The RXRX earnings report underperformed expectations due to lower revenue, higher R&D expenses, and a lack of reassuring pipeline updates, driving the stock price down. This decline reflects both company-specific issues (like missed forecasts and investor frustration) and broader sector pressures. From an investment standpoint, RXRX could be appealing for long-term investors with a high risk tolerance who believe in the transformative power of AI in drug discovery. The current dip might offer a discounted entry point, backed by a solid cash position. However, for short-term or risk-averse investors, the uncertainties around clinical trials and market sentiment make it a less compelling choice. As always, conduct your own research and align any decision with your investment goals and risk appetite.

Conclusion: A Speculative Bet with Big Potential

Recursion Pharmaceuticals embodies the high-risk, high-reward nature of biotech investing. Its cutting-edge AI platform, robust pipeline, and strong cash position position it for potential long-term success, particularly if it can translate its technology into marketed drugs. However, the recent earnings report exposes short-term vulnerabilities—revenue shortfalls, escalating costs, and pipeline uncertainties—that have understandably spooked investors.

For those with a high risk tolerance and a belief in AI’s transformative role in drug discovery, RXRX may represent an intriguing opportunity, especially at its current discounted valuation. Conversely, investors seeking quicker returns or lower volatility might find its clinical-stage uncertainties too daunting. As with any biotech investment, thorough due diligence is essential. RXRX’s future hinges on execution, and while the potential rewards are substantial, so too are the risks.

@TigerWire